|
Initially
approved February 26, 2001
Revised
October 28, 2002
Updated
October 29, 2004
POLICY
STATEMENT #111
BIOSAFETY
I.
Background
Research
laboratories working with microorganisms and/or recombinant
DNA technologies are special, often unique, work environments.
The materials being used may pose special risks to persons
working in or near the laboratory or to the environment
should the material escape the containment procedures
established for the laboratory. The University has therefore
established this policy in order to ensure the safe
handling of biohazardous agents, ensure the appropriate
assessment of potential risks, and reduce the opportunity
of personnel exposure or accidental environmental release.
II.
Policy
UNC
Charlotte is committed to the protection of the general
environment and the planning and implementation of control
practices for the prevention of laboratory-acquired
infections in all research programs involving biohazardous
agents. The University’s biosafety policy shall
be implemented through a Biosafety Manual and two biosafety
committees. The Manual provides specific procedures
and recommended practices for the handling of biohazardous
agents and recombinant DNA molecules. To ensure that
the University operates its facilities in compliance
with all applicable biosafety regulations and good laboratory
practices, a Biosafety Committee will establish procedures
for the registration of biohazardous agents and review
the use of such agents, and an Institutional Biosafety
Committee will review the use of recombinant DNA molecules.
Researchers who plan to use biohazardous agents or recombinant
DNA molecules are responsible for knowledge of the University’s
procedures.
The
Vice Chancellor for Research and Federal Relations has
responsibility for overseeing the implementation of
this policy and for submitting reports to NIH in compliance
with federal regulations regarding recombinant DNA.
III.
Biosafety Committee
The
Biosafety Committee is appointed by the Vice Chancellor
for Research and Federal Relations and periodically
reviews the Biosafety Manual and recommends revisions
to the Vice Chancellor for Research and Federal Relations.
The Committee establishes guidelines and procedures
for the registration of Biosafety Level (BSL)-2 or higher
agents and reviews and approves the use of BSL-3 agents.
(BSL-4 agents are not approved for use at UNC Charlotte.)
The Committee must approve in advance the procurement
and use of agents designated Select Agents [Attachment
A]. The Committee consists of not fewer than five
members so selected that they collectively have experience
and expertise in biohazardous agents and recombinant
DNA technology and the capability to assess safe practices
for the use of such agents and to identify any potential
risk to public health or the environment. The Committee
shall include two faculty members from the Department
of Biology, one faculty member from the Department of
Chemistry, and the Director of the Environmental/Occupational
Safety and Health Office, ex officio. The chair of the
Committee will be appointed by the Vice Chancellor for
Research and Federal Relations for a term not to exceed
two years.
IV.
Institutional Biosafety Committee
The
Institutional Biosafety Committee is responsible for
the review, approval, and oversight of recombinant DNA
research conducted at or sponsored by the University
in accordance with the NIH Guidelines for Research Involving
Recombinant DNA Molecules (NIH Guidelines). The Committee
shall consist of the members of the Biosafety Committee
and two additional members appointed by the Vice Chancellor
for Research and Federal Relations who are not otherwise
affiliated with the University and who represent the
interest of the surrounding community with respect to
health and protection of the environment. The Chair
of the Biosafety Committee also serves as Chair of the
Institutional Biosafety Committee. When the Committee
reviews experiments involving plants, animals, or human
subjects, the Vice Chancellor for Research and Federal
Relations will appoint additional members as necessary
to ensure that the membership is constituted in accordance
with the NIH Guidelines.
V.
Investigator Responsibility
Investigators
who have in their possession agents designated BSL-2
or -3 must register such agents with the Biosafety Committee.
The Biosafety Committee must approve in advance the
use of BSL-3 agents and the procurement and use of agents
designated Select Agents [Attachment
A]. The Biosafety Committee will not monitor BSL-1
agents, and UNC Charlotte does not permit research with
BSL-4 agents. In registering, investigators will document
that protocols and facilities do not jeopardize the
health and well being of themselves, their employees,
students, or the general public, and that all personnel
working in laboratories in which BSL-2 or -3 agents
are handled are familiar with the Biosafety Manual and
are appropriately trained.
Investigators
using recombinant DNA (rDNA) molecules must notify the
Office of Research Services, reporting the classification
of the rDNA research as specified by NIH guidelines.
If the reported classification requires review under
NIH guidelines, the Institutional Biosafety Committee
will conduct such review and issue approval as warranted.
Investigators
shall not possess nor permit the University to possess
on their behalf any biological agents, toxins, or delivery
systems not reasonably justified by prophylactic, protective,
bona fide research, or other peaceful purposes.
VI.
Office of Research Services
The
Office of Research Services provides administrative
support to the Biosafety Committee and the Institutional
Biosafety Committee, maintains the University Biosafety
Manual, manages all registration and reporting processes,
maintains appropriate records, and serves as liaison
with the University Brocker Health Center, the University
Environmental/Occupational Safety and Health Office,
and NIH in the ongoing implementation of the University’s
biosafety program. The Office of Research Services and
the Biosafety Committee will establish and publish procedures
for the implementation of this policy. These procedures
will be consistent continuously with regulations published
by federal, state, and local agencies.
|